According to the researchers, the new blood-clotting agent can help reduce internal bleeding by 97% and bleeding time by 99%.
An individual with major bleeding can die from anemia within minutes, however, it is comparatively easier to treat that person in a hospital environment. The problem is that first responders do not have the same equipment in an emergency. In a hospital, bleeding can be controlled by the blood-clotting agents such as platelets, however, they require careful refrigeration and storage, and thus, cannot be carried by first responders. Most of those individuals who suffer traumatic injuries due to internal bleeding.
Now, the research team from Harvard University has developed a new blood-clotting agent that can help people (who suffer traumatic injuries) survive long enough to reach a hospital. The new agent is portable and can be stored easily, as well as can be carried by an Individual. The newly developed blood-clotting agent is developed by Harvard University in collaboration with Case Western Reserve University, Beth Israel Deaconess Medical Center (BIDMC), and Massachusetts General Hospital. According to the researchers, the new blood-clotting agent can help reduce internal bleeding by 97% in mice.
Moreover, it can be stored at room temperature and reorganized into saline before injection. The new agent is named as HAPPI (Hemostatic Agents via Polymer Peptide Interfusion). It can be injected anywhere in the body and will help clot the wound. During this research, the researchers found that HAPPI reduced internal bleeding by 97% and bleeding time by 99%. According to the senior author of the study, Samir Mitragotri, the aim was to develop a tool that can help slow internal bleeding and can be carried by first responders or stored in an ambulance, helping people survive long enough to reach a hospital. The research was published in the Science Advances journal.